SUMMARY Factor IX concentrates have been widely advocated in the treatment of haemophilic patients with factor VIII inhibitors. Five such patients were given the 'activated' factor IX concentrate-factor VIII inhibitor bypassing activity (Feiba)-for 14 separate bleeding episodes. In six of the episodes, including two with external blood loss, bleeding progressed in spite of treatment. In none of the other eight episodes was there a prompt response, and it was not possible to ascribe a definite therapeutic effect.
Failure of factor VIII inhibitor bypassing activity (Feiba) A major complication of modern haemophilia therapy is the development of antibodies to factor VIII. This occurs in about 10% of treated patients, who become resistant to further treatment. Large doses of factor VIII may be effective in patients with low-titre inhibitors (Rizza and Biggs, 1973; Blatt et al., 1977) , and plasmapheresis using a continuousflow cell separator has been employed to lower the inhibitor titre sufficiently to allow factor VIIl replacement to be effective in others (Edson et al., 1973; Pintado et al., 1975) . Another and controversial approach has been the use of 'factor IX' concentrates. These contain the vitamin K dependent factors II, VII, IX, and X as well as factor XI, but some lack factor VII, and all types may become 'activated' during preparation. Such 'active' concentrates fail their thrombogenicity tests and are not used for the treatment of Christmas disease. It has been claimed that these accidentally activated factor IX concentrates, for example, Autoproplex, Hyland (Fekete et al., 1972; Kurczynski and Penner, 1974) , may contain a clotting factor intermediate which bypasses the site of action of factor VIII, and hence factor VIII antibodies, in the coagulation sequence and thus exerts a therapeutic effect in resistant haemophilic patients. Preparations purposely made to contain 'activated' factors have also been produced, for example, factor VIII inhibitor bypassing activity (Feiba, Immuno, Austria) , and it has been claimed that these also exert a therapeutic effect even in the case of external bleeding (Preston Received for publication 12 April 1978 12 April et al., 1977 . Recently, it has been claimed that nonactivated or 'routine' factor IX preparations (eg, Konyne, Cutter; Proplex, Hyland) may also be effective (Abildgaard et al., 1976; Kelly and Penner, 1976; Lowe et al., 1976) . In contrast to these reports Pollock and Lewis (1976) found no benefit from using these products in one patient.
In this paper we report the unsuccessful use of the activated 'factor IX' preparation Feiba in a series of episodes of bleeding in haemophilic patients with factor VIII antibodies.
Patients and methods
All five patients were severe haemophiliacs (procoagulant factor VIII 0 %) who had developed factor VIII antibodies previously. Routine coagulation tests were performed using standard techniques (Biggs, 1976) . Factor VIII inhibitor (antibody) assays were performed as described by Biggs and Bidwell (1959) . Immunoradiometric assay (IRMA) of factor VIII related antigen was carried out as described by Peake and Bloom (1977) .
Results
Fraction Feiba from seven different batches was used to treat 14 separate bleeding episodes. The clinical details are summarised in Table 1 . On six occasions therapy with Feiba was combined with factor VIII concentrate, as recommended by Schimpf et al. (1977) , at a dosage of 32-114 units/kg. In six of the 14 episodes, including two with external blood (15) loss, the bleeding progressed in spite of therapy with The whole blood clotting time (WBCT), proFeiba, and additional treatment was necessary. In thrombin time (PT), kaolin cephalin clotting time patient A, episode 3, this consisted of plasma-(KCCT), thrombin clotting time (TCT), and platelet pheresis using an Aminco continuous-flow cell count were performed before and after each inseparator, which lowered the inhibitor titre from fusion of Feiba. Factors II, V, VIII, and IX and 45 to 7 units/ml and enabled factor VIII concentrate fibrinogen assays were also performed. The results to be used successfully in large doses: 374 units/kg are summarised in Table 2 . Only a minimal shorteninitially, then 189 units/kg every 12 hours for four ing of the PT and KCCT was seen on each occasion. days. In the other eight episodes none showed a The greatest effect was observed on the WBCT, as prompt response to Feiba, and subsequent improve-previously reported by Elsinger (1977) . No evidence ment was slow, often not beginning until a few days of disseminated intravascular coagulation was after the start of treatment. In these episodes it observed, and platelet counts, fibrinogen, and factor was not possible to be certain of a definite thera-V levels remained unchanged. peutic effect of Feiba because slow resolution may For four of the bleeding episodes, no additional have been due to bed rest alone.
factor VIII was given, yet in one patient (C) there No evidence of disseminated intravascular coagulation was observed in any treatment episode.
group.bmj.com on July 7, 2017 -Published by http://jcp.bmj.com/ Downloaded from was an associated secondary rise in the factor VIII inhibitor titre. This phenomenon has been previously reported (Allain and Krieger, 1975; Mannucci et al., 1976) and is probably due to small quantities of factor VIII present in the prothrombin complex concentrates. The batch of Feiba used for our patient was examined using a sensitive immunoradiometric assay for factor VIII related antigen (FVIIIRAg), and 02-0-3 u/dl was detected. In addition, greater or lesser amounts were found in several other factor IX concentrates (Table 3) . Although FVIIIRAg is not the same antigen as that of procoagulant factor VIII the finding probably indicates contamination with the latter. In patients who received factor VIII concentrate, an anamnestic response was detected after three of the seven episodes (Table 1) . (Schimpf et al., 1977; . The reasons for the conflicting results are difficult to determine. As discussed by Blatt et al. (1977) (Elsinger, 1977) and, because it is related to the shortening of the clotting time of an antibody plasma, would be expected to be related more than the factor IX unit to a clinical effect. The methods of manufacture of most products, including Feiba, have not been released or may periodically change. The preparations may thus vary from product to product or even from batch to batch. Dosage schedules are therefore almost meaningless and entirely empirical. There is no reliable in-vitro method against which to assess a therapeutic effect although, as confirmed in the present study, there is usually moderate but incomplete correction of the whole blood clotting time (Elsinger, 1977) . There is a recent report that the newer and possibly less thrombogenic factor IX preparations may be correspondingly less effective in factor VIII antibody patients (Kelly and Penner, 1976) . On the credit side, and as confirmed in the present study, untoward side-effects are few although there has been a report of disseminated intravascular coagulation (Stenbjerg and Jorgensen, 1977a) , resistance to Feiba (Stenbjerg and Jorgensen, 1977b) , and one disturbing case of transient amaurosis (Rasche et al., 1977) . Anamnestic response of factor VIII antibody is less likely to occur than with factor VIII concentrate, and the treatment is certainly much less expensive. Recently, Brackmann et al. (1977) and Schimpf et al. (1977) have claimed that a combination of high doses of factor VIII and factor IX concentrates may be effective and that sustained use may even lead to the disappearance of the factor VIII antibodies, but this claim has yet to be substantiated. The high cost, for example £1000 a day for many months in one patient (Brackmann and Gormsen, 1977) , and the redistribution of blood products involved are undesirable aspects of this treatment programme.
The initial enthusiastic reports of the use of these activated factor IX preparations for the treatment of haemophilic patients with antibodies have led to their widespread uncontrolled use and the publication of several confirmatory reports. Our experience suggests that this impression may have been over optimistic, and there is no doubt that Feiba is not as effective as are factor VIII concentrates in normally responsive haemophiliacs. There is an urgent need for more controlled investigations of the manufacture and clinical effects of the materials, which will probably need to be assessed on a multicentre basis. If 
